Cargando…
Transporter modulation of molnupiravir and its metabolite β-D-N4-hydroxycytidine across the blood-brain barrier in a rat
BACKGROUND: The antiviral drug molnupiravir is an orally bioavailable prodrug of the nucleoside analog β-D-N4-hydroxycytidine (NHC), which is used to treat coronavirus disease 2019 (COVID-19). However, there is very little information on the barrier distribution of molnupiravir. Our hypothesis is th...
Autores principales: | Chang, Chun-Hao, Peng, Wen-Ya, Lee, Wan-Hsin, Yang, Ling, Lin, Tung-Yi, Yang, Muh-Hwa, Tsai, Tung-Hu |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10587300/ https://www.ncbi.nlm.nih.gov/pubmed/37857815 http://dx.doi.org/10.1038/s43856-023-00383-w |
Ejemplares similares
-
Transfer and biotransformation of the COVID-19 prodrug molnupiravir and its metabolite β-D-N4-hydroxycytidine across the blood-placenta barrier
por: Chang, Chun-Hao, et al.
Publicado: (2023) -
Oxidative DNA Damage by N(4)-hydroxycytidine, a Metabolite of the SARS-CoV-2 Antiviral Molnupiravir
por: Kobayashi, Hatasu, et al.
Publicado: (2022) -
Could chlorophyllins improve the safety profile of beta-d-N4-hydroxycytidine
versus N-hydroxycytidine, the active ingredient of the SARS-CoV-2 antiviral
molnupiravir?
por: Clark, Nicole F., et al.
Publicado: (2022) -
Biotransformation and brain distribution of the anti-COVID-19 drug molnupiravir and herb-drug pharmacokinetic interactions between the herbal extract Scutellaria formula-NRICM101
por: Chang, Chun-Hao, et al.
Publicado: (2023) -
Inhibitors of dihydroorotate dehydrogenase cooperate with molnupiravir and N4-hydroxycytidine to suppress SARS-CoV-2 replication
por: Stegmann, Kim M., et al.
Publicado: (2022)